Literature DB >> 15247562

Population-based surveillance of HIV-associated cancers: utility of cancer registry data.

Christina A Clarke1, Sally L Glaser.   

Abstract

Long-term cancer risks are uncertain in HIV-infected persons, particularly those using highly active antiretroviral therapy (HAART). Timely, population-based surveillance of HIV-associated malignancies in the United States has been challenging because of various data inadequacies. Cancer registries represent a resource for this surveillance, if uncertainties around accurate differentiation of HIV-associated and unassociated cancers can be resolved. To inform the utility of cancer registry data for classifying and monitoring HIV-associated cancers, the completeness and quality of cancer registry-available information about patient HIV status was assessed. For all 10,126 non-Hodgkin lymphomas (NHLs), 1497 Hodgkin lymphomas (HLs), and 895 anal cancers reported to the Greater San Francisco Bay Area registry during 1990-1998, 6 indicators of patient HIV status were retrieved from 2 cancer registry-available sources (cancer registry records, death records) and from linkage with the California AIDS registry. Cross-tabulations were used to examine the distributions of patients with evidence of positive HIV status by indicator and source. Together, 5 cancer registry-available HIV indicators identified 25% more presumed HIV-positive NHL patients and nearly 50% more HL and anal cancer patients than were detected by AIDS registry linkage. Eighty-three percent of NHL patients and at least half of HL and anal cancer patients were identified by multiple sources of HIV indicators, and most individual indicators agreed acceptably with others. However, optimal strategies for classifying HIV-associated patients differed by cancer site. At least in this region, cancer registry data represent a useful resource for monitoring HIV-associated lymphomas and anal cancer and may offer benefits over linkage-based means in the age of HAART.

Entities:  

Mesh:

Year:  2004        PMID: 15247562     DOI: 10.1097/00126334-200408150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  16 in total

1.  Age at cancer diagnosis for blacks compared with whites in the United States.

Authors:  Hilary A Robbins; Eric A Engels; Ruth M Pfeiffer; Meredith S Shiels
Journal:  J Natl Cancer Inst       Date:  2015-01-31       Impact factor: 13.506

2.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

Authors:  Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

3.  Time for oncologists to opt in for routine opt-out HIV testing?

Authors:  Elizabeth Y Chiao; Bruce J Dezube; Susan E Krown; William Wachsman; Malcolm V Brock; Thomas P Giordano; Ronald Mitsuyasu; Liron Pantanowitz
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

4.  Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases.

Authors:  Meredith S Shiels; Erik H Koritzinsky; Christina A Clarke; Gita Suneja; Lindsay M Morton; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

5.  The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

Authors:  Meredith S Shiels; Eric A Engels; Martha S Linet; Christina A Clarke; Jianmin Li; H Irene Hall; Patricia Hartge; Lindsay M Morton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-17       Impact factor: 4.254

6.  Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study.

Authors:  Theresa H M Keegan; Laura A McClure; James M Foran; Christina A Clarke
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.

Authors:  Sally L Glaser; Margaret L Gulley; Christina A Clarke; Theresa H Keegan; Ellen T Chang; Sarah J Shema; Fiona E Craig; Joseph A Digiuseppe; Ronald F Dorfman; Risa B Mann; Hoda Anton-Culver; Richard F Ambinder
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

8.  Hodgkin lymphoma incidence in ethnic enclaves in California.

Authors:  Sally L Glaser; Ellen T Chang; Christina A Clarke; Theresa H M Keegan; Juan Yang; Scarlett Lin Gomez
Journal:  Leuk Lymphoma       Date:  2015-06-18

9.  Time Trends in Rates of Hodgkin Lymphoma Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice?

Authors:  Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-27       Impact factor: 4.090

10.  Trends in primary central nervous system lymphoma incidence and survival in the U.S.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Caroline Besson; Christina A Clarke; Lindsay M Morton; Leticia Nogueira; Karen Pawlish; Elizabeth L Yanik; Gita Suneja; Eric A Engels
Journal:  Br J Haematol       Date:  2016-03-28       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.